Robertson K D, Ambinder R F
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
J Virol. 1997 Sep;71(9):6445-54. doi: 10.1128/JVI.71.9.6445-6454.1997.
Methylation-associated transcriptional repression is recognized in many settings and may play a role in normal differentiation and in tumorigenesis. Both sequence-specific and nonspecific mechanisms have been elaborated. Recently, we have presented evidence that methylation-associated inhibition of the Epstein-Barr virus (EBV) major latency promoter (BamHI C promoter or Cp) in Burkitt's lymphoma and Hodgkin's disease may play an important role in the pathogenesis of these tumors by protecting them from CD8+ cytotoxic T-cell immunosurveillance. The mechanism of transcriptional repression may relate to specific inhibition of the binding of a cellular transcription factor by methylation. To dissect the viral promoter with regard to transcriptional sensitivity to methylation, we have devised an assay that allows the methylation of discrete regions of reporter plasmids. During the course of the assay, methylation patterns appeared to be stable; there was no evidence of either spread or reversal of the imposed methylation pattern. Application of the assay to the 3.8-kb region upstream of the major EBV latency promoter with natural Cp reporter plasmids showed that sensitivity to methylation is not homogeneously distributed but is concentrated in two discrete regions. The first of these methylation-hypersensitive regions (MHRI) is the previously identified EBNA-2 response element, which includes the methylation-sensitive CBF2 binding site. The second (MHRII) is a sequence further downstream whose potential role in methylation-mediated transcriptional repression had been previously unsuspected. In chimeric enhancer/promoter plasmids, methylation of this downstream region was sufficient to virtually abolish simian virus 40 enhancer-driven transcription. Further dissection indicated that methylation of the EBNA-2 response element (MHRI) was sufficient to abolish EBNA-2-mediated Cp activity while methylation of a region including the EBNA-2 response element and downstream sequence (MHRI and MHRII) was sufficient to abolish all Cp-mediated reporter activity, including that driven by the EBNA-1-dependent enhancer in the origin of plasmid replication, oriP.
甲基化相关的转录抑制在多种情况下都有被认识到,并且可能在正常分化和肿瘤发生过程中发挥作用。序列特异性和非特异性机制都已得到阐述。最近,我们提供了证据表明,在伯基特淋巴瘤和霍奇金病中,甲基化对爱泼斯坦 - 巴尔病毒(EBV)主要潜伏启动子(BamHI C启动子或Cp)的抑制作用,可能通过保护肿瘤免受CD8 + 细胞毒性T细胞免疫监视,在这些肿瘤的发病机制中发挥重要作用。转录抑制的机制可能与甲基化对细胞转录因子结合的特异性抑制有关。为了剖析病毒启动子对甲基化的转录敏感性,我们设计了一种检测方法,该方法可以使报告质粒的离散区域发生甲基化。在检测过程中,甲基化模式似乎是稳定的;没有证据表明施加的甲基化模式会扩散或逆转。将该检测方法应用于带有天然Cp报告质粒的EBV主要潜伏启动子上游3.8 kb区域,结果表明对甲基化的敏感性并非均匀分布,而是集中在两个离散区域。这些甲基化高敏区域(MHRI)中的第一个是先前鉴定的EBNA - 2反应元件,其中包括甲基化敏感的CBF2结合位点。第二个(MHRII)是更下游的一个序列,其在甲基化介导的转录抑制中的潜在作用此前未被怀疑。在嵌合增强子/启动子质粒中,该下游区域的甲基化实际上足以消除猿猴病毒40增强子驱动的转录。进一步的剖析表明,EBNA - 2反应元件(MHRI)的甲基化足以消除EBNA - 2介导的Cp活性,而包括EBNA - 2反应元件和下游序列(MHRI和MHRII)的区域的甲基化足以消除所有Cp介导的报告活性,包括由质粒复制起点oriP中EBNA - 1依赖性增强子驱动的活性。